US2021261584A1PendingUtilityA1

Base-Modified Cytidine Nucleotides for Leukemia Therapy

Assignee: MEDIVIR ABPriority: Jun 21, 2018Filed: Jun 20, 2019Published: Aug 26, 2021

Est. expiryJun 21, 2038(~11.9 yrs left)· nominal 20-yr term from priority

Inventors:Pedro Pinho Bjorn Klasson John Öhd Mark Albertella

A61P 35/02C07F 9/65586C07D 405/04C12N 15/113A61K 31/7042C07H 19/10C07F 9/24

PatentIndex Score

Cited by

References

Claims

Abstract

Compounds of the formula Iwherein X is a bond or —CH2, and pharmaceutically acceptable salts thereof are useful in the parenteral treatment of leukemia, myelodysplastic syndrome or lymphoma, especially in patients presenting with cytarabine resistance and/or over 60 years of age.

Claims

exact text as granted — not AI-modified

1 . A compound of the formula I 
       
         
           
           
               
               
           
         
         wherein X is a bond or —CH 2 — 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         2 . A compound, or pharmaceutically acceptable salt thereof, according to  claim 1  with the formula IA: 
       
         
           
           
               
               
           
         
       
     
     
         3 . A compound, or pharmaceutically acceptable salt thereof, according to  claim 1  with the formula IB: 
       
         
           
           
               
               
           
         
       
     
     
         4 . A pharmaceutical composition comprising a compound of formula I, according to  claim 1 , or a pharmaceutically acceptable salt thereof and a vehicle or carrier therefor which is adapted for parenteral administration. 
     
     
         5 .- 7 . (canceled) 
     
     
         8 . A method for the treatment of a leukemia, myelodysplastic syndrome or a lymphoma in a patient comprising parenterally administering to a patient in need thereof an effective amount of a compound of formula I according to  claim 1 , or a pharmaceutically acceptable salt thereof. 
     
     
         9 . The method according to  claim 8 , wherein the leukemia is AML. 
     
     
         10 . The method according to  claim 9 , wherein the AML is cytarabine resistant and/or presents in a patient &gt;60 years of age. 
     
     
         11 . The method according to  claim 8 , wherein the patient is a mammal. 
     
     
         12 . The method according to  claim 8 , wherein the patient is a human. 
     
     
         13 . The method according to  claim 9 , wherein the patient is a human. 
     
     
         14 . The method according to  claim 10 , wherein the patient is a human.

Join the waitlist — get patent alerts

Track US2021261584A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.